Video

Role of Adjuvant Radiation Therapy in Melanoma

For High-Definition, Click

Adjuvant radiation therapy reduces the risk of local recurrence in patients with high-risk melanoma, notes Robert H. I. Andtbacka, MD, CM. However, this benefit does not translate into an extension in overall survival or control of distant recurrences. Additionally, Andtbacka notes, radiation therapy is accompanied by increased locoregional symptoms, with areas of the head and neck being less impacted compared with the groin.

If wound healing is sluggish as a result of obesity or other condition, radiation should not be considered, suggests Jeffrey A. Sosman, MD. Additionally, as a result of the added toxicity, treatment selection should focus on the patient’s health and the presences of extracapsular extension. However, even when extracapsular extensions are present, Andtbacka advises against radiation to groin areas.

In the ECOG-1609 trial, adjuvant ipilimumab is being compared with high-dose interferon alfa-2b in patients with high-risk stage III-IV melanoma. In this trial, enrollment does not exclude previous adjuvant radiation therapy, notes Omid Hamid, MD. As a result, findings from this study will provide further information on long-term outcomes with radiation therapy.

Related Videos
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Salman R. Punekar, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Thomas Marron, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
 Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD